# GSP Crop Science share price today (GSP Crop Science Ltd, NSE: GSPCROP) > GSP Crop Science share price today: ₹407.25 at the NSE close on 18 November 2026. GSP Crop Science (NSE: GSPCROP) is worth ₹1,893 crore and trades at a P/E of 22.3. > GSP Crop Science Ltd is reporting record margins. GSPCROP · Pesticides/Agrochemicals · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/gsp-crop-science-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Price: ₹407.25 - P/E: 22.3× (higher than 57% of the last 7 months) - Revenue (Sep 2026): ₹558 Cr (+19.5% on a year ago) - Profit (Sep 2026): ₹45.0 Cr (−22.4% on a year ago) - Operating margin: 13.3% (−6.6 points on a year ago) - ROCE: 19%, FY26 - ROIC: 13.3%, against a 12.0% cost of capital: +1.3 points - Profit that came in as cash: 128%, last 3 years Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the GSP Crop Science share price today? GSP Crop Science Ltd's share price was ₹407.25 at the close on 18 November 2026. It is in an uptrend that has just slipped below its 200-day average. That is 10.6% below its average price over the last 200 trading days. Since its first close in our records, on 17 April 2026, it has traded between ₹384 and ₹643, and at that close it sat 9% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 7 weeks running. Over the last 7 months the share price moved −3% while the NIFTY 500 moved +4%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at GSP Crop Science this quarter? 2. Operating margin down 7 points on a year earlier 13% in the September 2026 quarter, from 20%. 3. Highest quarterly revenue in 8 quarters Revenue of ₹558 crore in the September 2026 quarter is the highest of the last 8 quarters. ## What are GSP Crop Science's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), GSP Crop Science reported revenue of ₹558 crore, up 19.5% from ₹467 crore a year earlier, and a profit of ₹45.0 crore, down 22.4% from ₹58.0 crore. ### GSP Crop Science results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹558 crore | ₹467 crore | +19.5% | | Profit | ₹45.0 crore | ₹58.0 crore | −22.4% | | Earnings per share | ₹9.59 | ₹15.20 | −36.9% | | Operating margin | 13.3% | 19.9% | −6.6 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). GSP Crop Science's management discussed these results on a call held on 16 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the GSP Crop Science share price history? GSP Crop Science closed at ₹407.25 on 18 November 2026. Its highest weekly close since April 2026 was ₹626.60 on 28 August 2026. ### GSP Crop Science share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹437.95 | −7.0% | | 1 month ago · 19 Oct 2026 | ₹461.00 | −11.7% | | 6 months ago · 15 May 2026 | ₹427.80 | −4.8% | | Earliest weekly close in our records · 17 Apr 2026 | ₹421.75 | −3.4% | | Highest weekly close since April 2026 · 28 Aug 2026 | ₹626.60 | −35.0% | | Lowest weekly close since April 2026 · 1 Jul 2026 | ₹394.05 | +3.3% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (38 weekly closes from 17 April 2026 to 18 November 2026.) ## What is the latest news on GSP Crop Science? 18 Nov 2026: GSP Crop Science closed at ₹407.25, down 7.0% on the week and down 11.7% on the month. 16 Nov 2026: GSP Crop Science held its results call for July to September 2026. Management guided: Export share to 25% in 3 years alongside domestic growth. ### Earlier - Results for July to September 2026: Revenue up 19.5% and profit down 22.4% on a year earlier. - 11 Sep 2026: ex-date for a dividend of ₹1 a share. ## What dividend does GSP Crop Science pay? GSP Crop Science paid ₹1 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.25% at the ₹407.25 close on 18 November 2026. The last was a dividend of ₹1 a share, ex-date 11 September 2026. ### GSP Crop Science dividends since 1 April 2021 | Ex-date | Dividend per share | Type | | --- | --- | --- | | 11 Sep 2026 | ₹1 | Dividend | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. GSP Crop Science Ltd paid out 5% of its profit as dividends in FY26, and it paid a dividend in each of its last 7 reported years. (From the NSE corporate-actions record, read 18 November 2026.) ## What did GSP Crop Science management say on the latest results call? On the call for July to September 2026, held on 16 November 2026, GSP Crop Science's management guided: Export share to 25% in 3 years alongside domestic growth. > “Overall, profitability during the quarter was primarily impacted by higher raw material procurement costs, supply-related challenges, and the lower contribution from high-margin products.” > Shailesh Shah, Executive Director Finance and CFO, on the call for July to September 2026 ### What management guided - Q3 subdued with margin pressure for another quarter, normalizing in Q4 with sequential operating profit improvement with Q4 better than Q3. - Rabi sowing normalization within 30 days with outperformance versus last year despite macro challenges. - Brazil scale-up platform in 1-2 years, sizable business in 2-3 years on sufficient registration basket variability. - Flagged launch plus anchor-brand surround to drive remainder FY27 Rabi growth. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/58654-16-Nov-2026.pdf). (From the call for July to September 2026, 16 November 2026.) ## What to watch in GSP Crop Science's next results? When GSP Crop Science reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Sequential operating profit improvement through Q3 into Q4 pre-placement on Rabi patented placement and cost optimization execution. Management raised each of these on the latest results call. - Sequential operating profit improvement through Q3 into Q4 pre-placement on Rabi patented placement and cost optimization execution. - Rabi sowing normalization and reservoir recovery supporting flagged outperformance with second-paddy versus chilli grape pulse performance tracked. - Export mix progression and Brazil registration basket build with vessel transit easing sustainably lifting contribution. ## Which stock lists is GSP Crop Science on? GSP Crop Science is not on any of our India lists this week. ## Is GSP Crop Science profitable? GSP Crop Science Ltd earned ₹45.0 Cr of net profit in the Sep 2026 quarter, −22.4% on the same quarter a year earlier. Full-year FY26 profit was ₹95.0 Cr. Over 6 years profit has grown 28.6% a year on average. The Sep 2026 quarter's profit is 8.1% of that quarter's revenue. The same quarter a year earlier earned ₹58.0 Cr. 2 of the last 8 reported quarters were loss-making. For the full year, FY26 profit was ₹95.0 Cr (+15.9% on the year before). Why profit moved: revenue changed +19.5% on a year earlier and the margin moved −6.6 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −6.2% and revenue +12.6%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does GSP Crop Science make, and is it growing? GSP Crop Science Ltd reported ₹558 Cr of revenue in the Sep 2026 quarter, +19.5% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 6 years it has grown 9.0% a year on average. The last full year, FY26, came in at ₹1,517 Cr. The last four reported quarters add to ₹1,616 Cr. FY26 revenue was ₹1,517 Cr, +17.9% on the year before. Recent pace: the last four quarters grew +12.6% on average, against 9.0% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every ₹100 of sales does GSP Crop Science keep? GSP Crop Science Ltd's operating margin was 13.3% in the Sep 2026 quarter, 6.6 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 7 years it has been between 6.6% and 12.2%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed −6.8 percentage points on the year while gross margin changed −5.7 points. So the drop came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is GSP Crop Science's profit turning into cash? Over the last 3 years, 128% of GSP Crop Science Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹59.0 Cr of operating cash against ₹95.0 Cr of profit. After ₹77.0 Cr of spending on assets, free cash was −₹18.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 128% of profit came in as cash: the cash cycle got 31 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 2.5× depreciation over three years. The next section checks what that spending is building. ## Where does GSP Crop Science's cash go? GSP Crop Science Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 121 days in FY26, up from 90 days in FY21. It spent ₹179 Cr on assets over the last 3 years. Customers take 133 days to pay, and stock sits for 146 days on average. At FY26 sales of ₹1,517 Cr, each day of that cycle ties up about ₹4.2 Cr, so roughly ₹503 Cr is tied up in the business at any time. FY26: customers took 133 days to pay and stock sat for 146 days, about 4.8 months of sales sitting as stock, for a full cycle of 121 days, longer than FY21's 90. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 146 days. Customers pay about 133 days after that. Suppliers are paid at 158 days. Together that makes the 121-day cycle. Spending on assets: ₹179 Cr over the last 3 years, against ₹73.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹67.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is GSP Crop Science's P/E ratio, and how does it compare with its own history? GSP Crop Science Ltd's P/E is 22.3×, in the middle of its own history: higher than 57% of past readings. Its usual P/E (the middle reading) is 21.6×, over 7 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹18.28. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the GSP Crop Science business getting better or worse? GSP Crop Science Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does GSP Crop Science earn on its capital? GSP Crop Science Ltd earned a ROCE of 19% in FY26. That is up from a low of 8% in FY23. Its return on capital used (ROIC) is 1.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 6.3% net margin and 0.98× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 6.3% net margin × 0.98× asset turnover × 2.00× leverage (assets divided by equity) ≈ 12.3% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 13.3% − 12.0% = +1.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 13.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 14.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does GSP Crop Science have too much debt? GSP Crop Science Ltd has total debt of ₹294 Cr against shareholder equity of ₹834 Cr as of Sep 2026, so its debt is 0.35× its equity. Year by year, that ratio went from 0.68 in FY25 to 0.36 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the GSP Crop Science shareholding pattern? No group of GSP Crop Science Ltd's owners changed its stake by a full percentage point over the last 3 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. ## How far is GSP Crop Science from balance-sheet trouble? For GSP Crop Science Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does GSP Crop Science rank in its industry? 39.8 out of 100, rank 21 of 25 in Pesticides/Agrochemicals, with 63% of the evidence available. GSP Crop Science Ltd scores 39.8 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 21. There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. The three scored parts add up to the total exactly: 9 + 18.8 + 12 = 39.8 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is GSP Crop Science compared with? GSP Crop Science ranks 21 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 39.8 out of 100. 1. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) breaking out · Most evidence points up · 87% evidence 76.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 31.8% · Profit 38.7% · Operating margin change 3 points · 95% evidence Capital efficiency 21.3/25 · ROCE 22.8% (year to Mar 2026) · Operating margin 19.7% · 95% evidence Valuation 5.4/20 · P/E 55.2× · PEG n/a · 50% evidence Relative strength 18.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 44.3% · Strength vs NIFTY 500 (same reading) 21.3% · 1 year 177.2% · 100% evidence · 4 of 12 weeks ahead Exact sum: 31.3 + 21.3 + 5.4 + 18.6 = 76.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sharda Cropchem Ltd](https://www.sectoralpha.in/stocks/sharda-cropchem-ltd) SHARDACROP · basing · Most evidence points up · 100% evidence 66.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 17.3% · Profit 42.5% · Operating margin change 2 points · 100% evidence Capital efficiency 19.6/25 · ROCE 30.2% (year to Mar 2026) · Operating margin 15.6% · 100% evidence Valuation 11.5/20 · P/E 9.8× · PEG 2.26 · 100% evidence Relative strength 7.6/20 · Strength vs its industry (price vs its 52-week average, weekly) -5.2% · Strength vs NIFTY 500 (same reading) -21.1% · 1 year -12.6% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28.2 + 19.6 + 11.5 + 7.6 = 66.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) JUBLINGREA · quiet · Most evidence points up · 93% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.4/35 · Revenue 15.4% · Profit 21.9% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 11.4% (year to Mar 2026) · Operating margin 15.2% · 100% evidence Valuation 12.9/20 · P/E 26.7× · PEG 1.16 · 65% evidence Relative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 3.8% · Strength vs NIFTY 500 (same reading) -13.5% · 1 year -18.5% · 100% evidence · 2 of 12 weeks ahead Exact sum: 27.4 + 13.8 + 12.9 + 11.2 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) BAYERCROP · quiet · Evidence leans up · 85% evidence 63.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue -5% · Profit 22.5% · Operating margin change 4 points · 100% evidence Capital efficiency 19.3/25 · ROCE 29.1% (year to Mar 2026) · Operating margin 17.4% · 100% evidence Valuation 10.6/20 · P/E 20.2× · PEG 2.21 · 100% evidence Relative strength 8.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -22.1% · 1 year -26.2% · 25% evidence · 0 of 12 weeks ahead Exact sum: 24.5 + 19.3 + 10.6 + 8.6 = 63 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) DHANUKA · quiet · Evidence leans up · 100% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue 0% · Profit 0.7% · Operating margin change 0 points · 100% evidence Capital efficiency 19.8/25 · ROCE 25.9% (year to Mar 2026) · Operating margin 23.3% · 100% evidence Valuation 11.4/20 · P/E 14.8× · PEG 2.07 · 100% evidence Relative strength 13.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 0.8% · Strength vs NIFTY 500 (same reading) -16.1% · 1 year -23.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10 + 19.8 + 11.4 + 13.5 = 54.7 · What this means: Relative strength against the index is -16.1%, and revenue and profit growth are weak. 6. [Advance Agrolife Ltd](https://www.sectoralpha.in/stocks/advance-agrolife-ltd) ADVANCE · losing its lead · Evidence leans up · 68% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.0/35 · Revenue 49.4% · Profit 55.2% · Operating margin change -4 points · 100% evidence Capital efficiency 13.7/25 · ROCE 19.6% (year to Mar 2026) · Operating margin 7.7% · 100% evidence Valuation 10.1/20 · P/E 17.4× · PEG n/a · 15% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 2.3% · 1 year -8.5% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19 + 13.7 + 10.1 + 11.9 = 54.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Punjab Chemicals & Crop Protection Ltd](https://www.sectoralpha.in/stocks/punjab-chemicals-crop-protection-ltd) PUNJABCHEM · quiet · Evidence leans up · 75% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 14% · Profit 13.2% · Operating margin change -1 points · 100% evidence Capital efficiency 13.2/25 · ROCE 18.6% (year to Mar 2026) · Operating margin 9.2% · 100% evidence Valuation 11.0/20 · P/E 17.9× · PEG n/a · 50% evidence Relative strength 9.2/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -19% · 1 year -34.1% · 25% evidence · 3 of 12 weeks ahead Exact sum: 19.6 + 13.2 + 11 + 9.2 = 53 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Dharmaj Crop Guard Ltd](https://www.sectoralpha.in/stocks/dharmaj-crop-guard-ltd) DHARMAJ · quiet · Evidence leans up · 75% evidence 52.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.5/35 · Revenue 3.8% · Profit 14.3% · Operating margin change -2 points · 100% evidence Capital efficiency 14.7/25 · ROCE 16.8% (year to Mar 2026) · Operating margin 7.2% · 100% evidence Valuation 13.2/20 · P/E 15.1× · PEG n/a · 50% evidence Relative strength 10.0/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -9.7% · 1 year -0.9% · 25% evidence · 5 of 12 weeks ahead Exact sum: 14.5 + 14.7 + 13.2 + 10 = 52.4 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 9. [Best Agrolife Ltd](https://www.sectoralpha.in/stocks/best-agrolife-ltd) BESTAGRO · quiet · Evidence leans up · 90% evidence 52.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue -19.6% · Profit 100% · Operating margin change 10 points · 100% evidence Capital efficiency 10.0/25 · ROCE 5.2% (year to Mar 2026) · Operating margin 24.8% · 100% evidence Valuation 11.3/20 · P/E 10.8× · PEG n/a · 50% evidence Relative strength 6.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -4.7% · Strength vs NIFTY 500 (same reading) -20.8% · 1 year -26.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.7 + 10 + 11.3 + 6 = 52 · What this means: Earnings are strong; relative strength in its sector is -4.7% and the one-year return is -26.5%. 10. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) MOL · quiet · Evidence leans down · 68% evidence 49.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue -5.2% · Profit 100% · Operating margin change 2 points · 100% evidence Capital efficiency 7.7/25 · ROCE 6.7% (year to Mar 2026) · Operating margin 10.9% · 100% evidence Valuation 10.4/20 · P/E 15.6× · PEG n/a · 15% evidence Relative strength 10.7/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -2.3% · 1 year -23.9% · 25% evidence · 8 of 12 weeks ahead Exact sum: 20.9 + 7.7 + 10.4 + 10.7 = 49.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Excel Industries Ltd](https://www.sectoralpha.in/stocks/excel-industries-ltd) EXCELINDUS · losing its lead · Evidence leans down · 68% evidence 49.0 out of 100 Growth Capital Valuation Relative 12. [UPL Ltd](https://www.sectoralpha.in/stocks/upl-ltd) UPL · basing · Evidence leans down · 82% evidence 48.9 out of 100 Growth Capital Valuation Relative 13. [Rallis India Ltd](https://www.sectoralpha.in/stocks/rallis-india-ltd) RALLIS · quiet · Evidence leans down · 85% evidence 47.9 out of 100 Growth Capital Valuation Relative 14. [Shivalik Rasayan Ltd](https://www.sectoralpha.in/stocks/shivalik-rasayan-ltd) SHIVALIK · turning · Evidence leans down · 67% evidence 47.9 out of 100 Growth Capital Valuation Relative 15. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) BHAGCHEM · quiet · Evidence leans down · 83% evidence 47.7 out of 100 Growth Capital Valuation Relative 16. [Epigral Ltd](https://www.sectoralpha.in/stocks/epigral-ltd) EPIGRAL · quiet · Evidence leans down · 75% evidence 46.8 out of 100 Growth Capital Valuation Relative 17. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) IPL · quiet · Evidence leans down · 75% evidence 46.0 out of 100 Growth Capital Valuation Relative 18. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) SUMICHEM · quiet · Evidence leans down · 85% evidence 43.7 out of 100 Growth Capital Valuation Relative 19. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) INSECTICID · quiet · Evidence leans down · 90% evidence 42.8 out of 100 Growth Capital Valuation Relative 20. [Bharat Rasayan Ltd](https://www.sectoralpha.in/stocks/bharat-rasayan-ltd) BHARATRAS · basing · Evidence leans down · 90% evidence 42.4 out of 100 Growth Capital Valuation Relative 21. GSP Crop Science Ltd this page GSPCROP · quiet · Evidence leans down · 63% evidence 39.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.0/43.75 · Revenue 13.2% · Profit -12.4% · Operating margin change -7 points · 100% evidence Capital efficiency 18.8/31.25 · ROCE 18.9% (year to Mar 2026) · Operating margin 13.3% · 100% evidence Valuation 12.0/25 · P/E 22.3× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 9 + 18.8 + 12 = 39.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 22. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) PIIND · quiet · Most evidence points down · 75% evidence 34.5 out of 100 Growth Capital Valuation Relative 23. [NACL Industries Ltd](https://www.sectoralpha.in/stocks/nacl-industries-ltd) NACLIND · basing · Most evidence points down · 90% evidence 32.9 out of 100 Growth Capital Valuation Relative 24. [Heranba Industries Ltd](https://www.sectoralpha.in/stocks/heranba-industries-ltd) HERANBA · quiet · Most evidence points down · 71% evidence 31.9 out of 100 Growth Capital Valuation Relative 25. [Astec Lifesciences Ltd](https://www.sectoralpha.in/stocks/astec-lifesciences-ltd) ASTEC · quiet · Most evidence points down · 71% evidence 31.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pesticides/Agrochemicals](https://www.sectoralpha.in/sectors/pesticides-agrochemicals), all 25 compared on one page. ## Which companies are close to GSP Crop Science in size? GSP Crop Science is the 13th largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: NACL Industries, Bhagiradha Chemicals & Industries and Titan Biotech. Just below it: Bharat Rasayan, Insecticides India and Meghmani Organics. ### Pesticides/Agrochemicals companies close in size 1. [NACL Industries Ltd](https://www.sectoralpha.in/stocks/nacl-industries-ltd) ₹2,732 crore 2. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) ₹2,331 crore 3. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) ₹2,135 crore 4. GSP Crop Science Ltd ₹1,895 crore 5. [Bharat Rasayan Ltd](https://www.sectoralpha.in/stocks/bharat-rasayan-ltd) ₹1,595 crore 6. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) ₹1,586 crore 7. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) ₹1,349 crore [All 25 Pesticides/Agrochemicals companies, largest first](https://www.sectoralpha.in/sectors/pesticides-agrochemicals#all-companies) ### Companies close in size in other industries 1. [Vinyas Innovative Technologies Ltd](https://www.sectoralpha.in/stocks/vinyas-innovative-technologies-ltd) ₹1,898 crore · Aerospace & Defence - Equipments 2. [Greenpanel Industries Ltd](https://www.sectoralpha.in/stocks/greenpanel-industries-ltd) ₹1,898 crore · Plywood Boards/Laminates 3. GSP Crop Science Ltd ₹1,895 crore 4. [Kross Ltd](https://www.sectoralpha.in/stocks/kross-ltd) ₹1,888 crore · Auto Ancillaries - Transmission 5. [Bodal Chemicals Ltd](https://www.sectoralpha.in/stocks/bodal-chemicals-ltd) ₹1,888 crore · Dyes & Pigments ## What else do people ask about GSP Crop Science? ### What is GSP Crop Science's share price today? GSP Crop Science Ltd's share price is ₹407.25. The whole company is worth ₹1,893 Cr on the market. In the last 52 weeks it traded between ₹384 to ₹643; today it is 9% of the way up from the low, 10.6% below its 200-day average. The price has been rising for 32 weeks (as of 18 November 2026). ### What were GSP Crop Science's latest quarterly results? GSP Crop Science Ltd reported revenue of ₹558 Cr and net profit of ₹45.0 Cr for the Sep 2026 quarter. Revenue rose 19.5% and profit fell 22.4% compared with a year earlier. Earnings per share were ₹9.59. The operating margin was 13.3%, 6.6 percentage points lower than a year earlier (as of 18 November 2026). ### What is GSP Crop Science's market cap? GSP Crop Science Ltd's market capitalisation is ₹1,893 Cr at a share price of ₹407.25. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is GSP Crop Science performing? GSP Crop Science Ltd's share price is in an uptrend that has just slipped below its 200-day average. In its latest quarter, revenue rose 19.5% and profit fell 22.4% compared with a year earlier. This describes what the data did, not a rating (as of 18 November 2026). ### Is GSP Crop Science in an uptrend? Yes, the price has been rising for 32 weeks (stage 2 of 4), 10.6% below its 200-day average, and 9% of the way up its 52-week range. A share price tends to move through four phases: moving sideways, rising, stalling and falling (as of 18 November 2026). ### Will GSP Crop Science's share price go up? This page does not forecast GSP Crop Science Ltd's share price. What it shows instead: the share price is ₹407.25, and it has been rising for 32 weeks. Its P/E of 22.3× is higher than 57% of its own last 1 years (as of 18 November 2026). ### Who owns GSP Crop Science? Promoters own 71.7% of GSP Crop Science Ltd, foreign institutions 9.6%, domestic institutions 0.0% and the public 18.7% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026). ### Does GSP Crop Science have too much debt? GSP Crop Science Ltd has a moderate amount of debt: its debt is 0.34× its equity, and its operating profit is 5 times its interest bill. FY26 borrowings were ₹262 Cr against equity of ₹772 Cr. Keep that borrowing in mind when reading the returns on this page (as of 18 November 2026). ### Where is GSP Crop Science in its business cycle? GSP Crop Science Ltd's FY26 operating margin was 12.2%, against a 7-year range of 6.6% to 12.2%. The latest quarter was 13.3%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the GSP Crop Science story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is GSP Crop Science a stock worth studying right now? What the numbers show: GSP Crop Science Ltd is reporting record margins. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a GSP Crop Science share price forecast for 2026? What management itself guided: Export share to 25% in 3 years alongside domestic growth. This is research, not advice. We’re not SEBI-registered.